BioSante Pharmaceuticals Comments On Study Showing No Increased Risk Of Breast Cancer In Women Using Testosterone For Low Libido

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), which is developing a testosterone gel (LibiGel®) to treat hypoactive sexual desire disorder (HSDD) in women, is pleased to comment on results in a paper published in the July issue of The Journal of Sexual Medicine showing testosterone has no effect on the incidence of invasive breast cancer among menopausal women who use testosterone to improve sexual function. The study, led by Susan Davis, M.D.

Source: BioSante Pharmaceuticals Comments On Study Showing No Increased Risk Of Breast Cancer In Women Using Testosterone For Low Libido